{"id":"NCT04165824","sponsor":"Mitsubishi Tanabe Pharma America Inc.","briefTitle":"Safety Study of Oral Edaravone Administered in Subjects With ALS","officialTitle":"Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-18","primaryCompletion":"2021-10-07","completion":"2021-10-07","firstPosted":"2019-11-18","resultsPosted":"2022-08-29","lastUpdate":"2025-09-08"},"enrollment":185,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["ALS"],"interventions":[{"type":"DRUG","name":"MT-1186","otherNames":["Oral edaravone"]}],"arms":[{"label":"MT-1186","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) over 24 and 48 weeks.","primaryOutcome":{"measure":"Number of Treatment Emergency Adverse Events","timeFrame":"up to 48 Weeks","effectByArm":[{"arm":"MT-1186","deltaMin":961,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":53,"countries":["United States","Canada","France","Germany","Italy","Japan"]},"refs":{"pmids":["36504406"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":48,"n":185},"commonTop":["Fall","Muscular weakness","Constipation","Back pain","Dysphagia"]}}